Trending Topic

5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

touchDERMATOLOGY coverage from EADV 2024: Twice-daily continuous application of ruxolitinib cream, a topical selective JAK1/JAK2 inhibitor, has been reported to be safe and effective in treating children with mild to moderate atopic dermatitis (AD) over an 8-week period in the TRuE-AD studies.1,2 In this interview, we talk with Dr Amy Paller from the Northwestern University […]

Cantharidin solution (0.7%) drug-device combination and its use in molluscum contagiosum: James Del Rosso

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 10th 2024

Molluscum contagiosum, a common skin infection caused by a poxvirus (molluscum contagiosum virus), usually resulting in benign, mild skin disease characterized by lesions appearing anywhere on the body. In this interview, Dr. James Del Rosso (JDR Dermatology Research, Las Vegas, Nevada, USA, and President-Elect American Acne & Rosacea Society) shares insights into molluscum contagiosum, and addresses the current unmet needs in its treatment. Dr. Del Rosso also provides an in-depth look at the cantharidin solution (0.7%) drug-device combination, discussing its role and effectiveness in treating this condition.

Watch the expert perspective interview with Dr James Del Rosso on the efficacy and safety findings from CAMP-1 and CAMP-2 and cantharidin solution (0.7%) FDA approval.

Questions:

  1. Could you tell us a little about molluscum contagiosum and the unmet needs in its treatment?
  2. Could you describe the cantharidin solution (0.7%) drug-device combination?

Disclosures: James Del Rosso is a consultant and speaker for Verrica pharmaceuticals.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup